Inhibition of Estrogen Receptor Signaling as a Strategy for Radiosensitization of ER plus Breast Cancers

被引：0
|
作者：
Michmerhuizen, A. R. [1 ]
Pesch, A. [1 ]
Schwartz, R. [1 ]
Wilder-Romans, K. [1 ]
Liu, M. [1 ]
Harold, A. [1 ]
Azaria, R. [1 ]
Hayes, D. [1 ]
Rae, J. [1 ]
Pierce, L. J. [2 ]
Schmidt, D. R. [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2507
引用
收藏
页码：E253 / E253
页数：1
相关论文
共 50 条
  • [21] Inhibition of estrogen receptor reduces connexin 43 expression in breast cancers
    Tsai, Cheng-Fang
    Cheng, Yu -Kai
    Lu, Dah-Yuu
    Wang, Shu-Lin
    Chang, Chen-Ni
    Chang, Pei-Chun
    Yeh, Wei-Lan
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2018, 338 : 182 - 190
  • [22] Hyperthermia plus radiotherapy in Estrogen receptor positive (ER plus ) breast cancer; before or after?
    Joveini, Zahra
    Behrouzkia, Zhaleh
    Aghdam, Reza Zohdi
    CANCER RESEARCH, 2017, 77 (22)
  • [23] Proteasome inhibition represses ERα gene expression in ER plus cells: a new link between proteasome activity and estrogen signaling in breast cancer
    Powers, G. L.
    Ellison-Zelski, S. J.
    Casa, A. J.
    Lee, A. V.
    Alarid, E. T.
    ONCOGENE, 2010, 29 (10) : 1509 - 1518
  • [24] Serum proteomic profiling distinguishes estrogen receptor (ER) positive and ER negative breast cancers.
    Sun, M
    Sun, M
    Lyons-Weiler, J
    Lokshin, AE
    Modugno, F
    Marks, J
    Bigbee, WL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 23S - 23S
  • [25] Discovery of SAR439859, an orally bioavailable Selective Estrogen Receptor Degrader (SERD) to treat ER plus breast cancers
    Elahmad, Youssef
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [26] A radiosensitizer screen identifies a novel role for MDM2 inhibition in the radiosensitization of ER plus breast cancers in a p53 dependent manner
    Ritter, Cassandra L.
    Chandler, Benjamin C.
    Pesch, Andrea M.
    Michmerhuizen, Anna R.
    Hirsh, Nicole
    Zhang, Amanda
    Ward, Tanner
    Cremona, Mattia
    Hennessy, Bryan
    Pierce, Lori J.
    Speers, Corey W.
    CANCER RESEARCH, 2020, 80 (16)
  • [27] Estrogen Receptor Alpha Negative (ER-) Breast Cancer Stem Cells in ER plus Cell Lines and Primary Cancers Are Enriched by Tamoxifen Therapy
    O'Brien, C. S.
    Howell, S. J.
    Gandhi, A.
    Gee, J.
    Lykkesfeldt, A.
    Nicholson, R. I.
    Clarke, R. B.
    CANCER RESEARCH, 2010, 70
  • [28] Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER plus Breast Cancer
    Traphagen, Nicole A.
    Schwartz, Gary N.
    Tau, Steven
    Roberts, Alyssa M.
    Jiang, Amanda
    Hosford, Sarah R.
    Marotti, Jonathan D.
    Goen, Abigail E.
    Romo, Bianca A.
    Johnson, Anneka L.
    Duffy, Emily-Claire K.
    Demidenko, Eugene
    Heverly, Paul
    Mosesson, Yaron
    Soucy, Shannon M.
    Kolling, Fred
    Miller, Todd W.
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3717 - 3728
  • [29] Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER plus breast cancer
    Traphagen, Nicole
    Schwartz, Gary
    Tau, Steven
    Roberts, Alyssa
    Jiang, Amanda
    Hosford, Sarah
    Marotti, Jonathan
    Goen, Abigail
    Romo, Bianca
    Johnson, Anneka
    Duffy, Emily
    Demidenko, Eugene
    Heverly, Paul
    Mosesson, Yaron
    Soucy, Shannon
    Kolling, Fred
    Miller, Todd
    CANCER RESEARCH, 2024, 84 (09)
  • [30] ER-α36, a variant of ER-α, is the estrogen receptor that mediates mitogenic estrogen signaling in breast cancer cells
    Ding, L.
    Zhang, X. T.
    Wang, Z. Y.
    CANCER RESEARCH, 2009, 69 (02) : 68S - 68S
12345